SC
TRVI icon

Shay Capital’s Trevi Therapeutics TRVI Stock Holding History

Shay Capital’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-93,962
Closed -$314K – 429
2024
Q3 		$314K Buy
93,962
+5,500
+6% +$16.3K 0.04% 216
2024
Q2 		$264K Sell
88,462
-25,200
-22% -$70K 0.04% 204
2024
Q1 		$392K Buy
+113,662
New +$254K 0.06% 209

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Shay Capital's TRVI Position: Q4 2024 in Review

Shay Capital sold out of Trevi Therapeutics (TRVI) in Q4 2024, closing a stake of 93,962 shares — an estimated $314K sold.

Shay Capital first reported a position in TRVI in Q1 2024 and held it in 3 quarters. The position peaked at $392K in Q1 2024. 110 funds tracked by Wall St. Rank hold TRVI as of Q4 2024.

  • Shay Capital reported no remaining Trevi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Shay Capital sold 93,962 Trevi Therapeutics shares in Q4 2024, an estimated $314K.
  • Shay Capital first reported a position in Trevi Therapeutics in Q1 2024 and held it in 3 quarters.
  • Shay Capital's Trevi Therapeutics position peaked at $392K in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2024.

Based on Shay Capital's 13F filing for Q4 2024, filed 14 Feb 2025.